JP2023514788A5 - - Google Patents

Info

Publication number
JP2023514788A5
JP2023514788A5 JP2022551251A JP2022551251A JP2023514788A5 JP 2023514788 A5 JP2023514788 A5 JP 2023514788A5 JP 2022551251 A JP2022551251 A JP 2022551251A JP 2022551251 A JP2022551251 A JP 2022551251A JP 2023514788 A5 JP2023514788 A5 JP 2023514788A5
Authority
JP
Japan
Prior art keywords
cells
subject
nkt cells
nkt
hed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022551251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514788A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/019773 external-priority patent/WO2021173900A1/en
Publication of JP2023514788A publication Critical patent/JP2023514788A/ja
Publication of JP2023514788A5 publication Critical patent/JP2023514788A5/ja
Pending legal-status Critical Current

Links

JP2022551251A 2020-02-28 2021-02-26 リンパ球集団およびそれを生産するための方法 Pending JP2023514788A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062983005P 2020-02-28 2020-02-28
US62/983,005 2020-02-28
US202063009050P 2020-04-13 2020-04-13
US63/009,050 2020-04-13
US202063123054P 2020-12-09 2020-12-09
US63/123,054 2020-12-09
PCT/US2021/019773 WO2021173900A1 (en) 2020-02-28 2021-02-26 Lypmphocyte population and methods for producing same

Publications (2)

Publication Number Publication Date
JP2023514788A JP2023514788A (ja) 2023-04-10
JP2023514788A5 true JP2023514788A5 (OSRAM) 2024-03-01

Family

ID=75108879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551251A Pending JP2023514788A (ja) 2020-02-28 2021-02-26 リンパ球集団およびそれを生産するための方法

Country Status (11)

Country Link
US (1) US20230096897A1 (OSRAM)
EP (1) EP4110902A1 (OSRAM)
JP (1) JP2023514788A (OSRAM)
KR (1) KR20220148859A (OSRAM)
CN (1) CN115516085A (OSRAM)
AU (1) AU2021227925A1 (OSRAM)
BR (1) BR112022016803A2 (OSRAM)
CA (1) CA3168378A1 (OSRAM)
IL (1) IL295952A (OSRAM)
MX (1) MX2022010674A (OSRAM)
WO (1) WO2021173900A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021222385A1 (en) * 2020-04-29 2021-11-04 Avm Biotechnology, Llc Glucocorticoid receptor (gr) modulators for treating a sars-cov-2 virus
US20240358829A1 (en) * 2021-09-01 2024-10-31 Avm Biotechnology, Llc Lymphocyte Population and Methods for Producing Same
CN114561362B (zh) * 2021-12-28 2023-12-15 江西省疾病预防控制中心 一种人源肾综合征出血热汉坦病毒分离方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2073009A1 (en) * 2007-12-19 2009-06-24 Cell Med Research GMBH Method for T, NK and NKT cells
EP2647384B1 (en) * 2010-12-02 2018-05-23 Riken IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH alpha CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM V alpha-J alpha , AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS
WO2015112793A2 (en) * 2014-01-27 2015-07-30 St. Jude Children's Research Hospital, Inc. Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof
ES2954311T3 (es) * 2017-04-01 2023-11-21 Avm Biotechnology Llc Reemplazo de un preacondicionamiento citotóxico antes de una inmunoterapia celular
EP3827074A2 (en) * 2018-07-26 2021-06-02 Ospedale Pediatrico Bambino Gesù Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use
WO2020028444A1 (en) * 2018-07-30 2020-02-06 University Of Southern California Improving the efficacy and safety of adoptive cellular therapies
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies

Similar Documents

Publication Publication Date Title
Peng et al. CTLs heterogeneity and plasticity: implications for cancer immunotherapy
Qi et al. Gamma delta T cells and their pathogenic role in psoriasis
JP2020518289A5 (OSRAM)
CA2446981C (fr) Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
Earle et al. In vitro expanded human CD4+ CD25+ regulatory T cells suppress effector T cell proliferation
JP2022002517A (ja) 非造血組織常在性γδ T細胞の増幅および該細胞の使用
CN104245923B (zh) 同种异型抗原‑反应性调节t细胞的增殖
EP3878950B1 (en) Method for culturing natural killer cells using t cells
US20220380727A1 (en) Generation of engineered regulatory t cells
US20190351019A1 (en) Steroid administration and immunotherapy
JP5937003B2 (ja) 免疫介在性疾患における臨床応用のための、抑制機能の高められた制御性t細胞のエクスビボ増加方法
JP2016539929A5 (OSRAM)
JP2000509604A (ja) サプレッサー細胞集団を生成するためのインターロイキン―10の使用
JP2024513522A5 (OSRAM)
JP2001149069A (ja) ナチュラルキラー細胞の増殖方法
TW202325320A (zh) 用於產生原代免疫細胞之方法
Raheem et al. The emerging role of tissue regulatory T cells in tissue repair and regeneration
US20220175834A1 (en) Methods for culturing immune cells
JP2023524434A5 (OSRAM)
Deng et al. Prospects and limitations of NK cell adoptive therapy in clinical applications
Gao et al. Induced regulatory T cells modified by knocking down T-bet in combination with ectopic expression of inhibitory cytokines effectively protect graft-versus-host disease
Pothoven et al. Rapamycin-conditioned donor dendritic cells differentiate CD4+ CD25+ Foxp3+ T cells in vitro with TGF-β1 for islet transplantation
JP2024533093A5 (OSRAM)
CN115516085A (zh) 淋巴细胞群体以及用于产生所述淋巴细胞群体的方法
JP2019508056A5 (OSRAM)